[S02DA03, antipyrine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Indapamide.]
[J01GA01, streptomycin, Indapamide may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Indapamide may increase the excretion rate of Sucralfate which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CG01, sulbactam, Indapamide may increase the excretion rate of Sulbactam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Indapamide.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Indapamide.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Indapamide.]
[M01AB02, sulindac, The therapeutic efficacy of Indapamide can be decreased when used in combination with Sulindac.]
[N05AL01, sulpiride, The risk or severity of orthostatic hypotension can be increased when Indapamide is combined with Sulpiride.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Indapamide.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Indapamide.]
[M01AX04, apazone, The therapeutic efficacy of Indapamide can be decreased when used in combination with Azapropazone.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Indapamide.]
[N05CD07, temazepam, Indapamide may increase the excretion rate of Temazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Terbutaline.]
[B01AE07, dabigatran etexilate, Indapamide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.]
[G03BA03, testosterone, Indapamide may increase the excretion rate of Testosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Tetrabenazine.]
[S03AA02, tetracycline, Indapamide may increase the excretion rate of Tetracycline which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Lurasidone.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Indapamide.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Indapamide is combined with Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Indapamide may increase the excretion rate of Thiabendazole which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Eribulin.]
[R06AD03, thiethylperazine, Indapamide may increase the excretion rate of Thiethylperazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA19, thiopental, The risk or severity of hypotension and orthostatic hypotension can be increased when Thiopental is combined with Indapamide.]
[N05AB08, thioproperazine, Thioproperazine may decrease the antihypertensive activities of Indapamide.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Thiothixene.]
[G04BE06, moxisylyte, Indapamide may increase the excretion rate of Moxisylyte which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL03, tiapride, Indapamide may increase the excretion rate of Tiapride which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC05, ticlopidine, Indapamide may increase the excretion rate of Ticlopidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX01, tilidine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Tilidine.]
[S01ED01, timolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Timolol.]
[P01AB02, tinidazole, Indapamide may increase the excretion rate of Tinidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA12, tobramycin, Indapamide may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Indapamide.]
[M02AX02, tolazoline, The therapeutic efficacy of Indapamide can be increased when used in combination with Tolazoline.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Indapamide.]
[M02AA21, tolmetin, The therapeutic efficacy of Indapamide can be decreased when used in combination with Tolmetin.]
[N02AX02, tramadol, Indapamide may increase the excretion rate of Tramadol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypotensive activities of Indapamide.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Indapamide.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Indapamide.]
[S01BA05, triamcinolone, Triamcinolone may increase the hypokalemic activities of Indapamide.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Indapamide may increase the excretion rate of Triazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Indapamide can be increased when used in combination with Trichlormethiazide.]
[A03AB12, mepenzolate, The serum concentration of Indapamide can be increased when it is combined with Mepenzolate.]
[A16AX12, trientine, Indapamide may increase the excretion rate of Triethylenetetramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB06, trifluoperazine, Trifluoperazine may decrease the antihypertensive activities of Indapamide.]
[S01AD02, trifluridine, Indapamide may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AA05, triflupromazine, The serum concentration of Indapamide can be increased when it is combined with Triflupromazine.]
[D07AC02, fluclorolone, Fluclorolone may increase the hypokalemic activities of Indapamide.]
[N04AA01, trihexyphenidyl, The serum concentration of Indapamide can be increased when it is combined with Trihexyphenidyl.]
[R03BA07, mometasone, Mometasone may increase the hypokalemic activities of Indapamide.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Trimebutine.]
[S01ED04, metipranolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Metipranolol.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Indapamide.]
[C02BA01, trimethaphan, The therapeutic efficacy of Indapamide can be increased when used in combination with Trimethaphan.]
[J01EA01, trimethoprim, Indapamide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Indapamide.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Indapamide.]
[A03BB01, butylscopolamine, The serum concentration of Indapamide can be increased when it is combined with Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Indapamide can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, Vilazodone may decrease the antihypertensive activities of Indapamide.]
[C09CA09, azilsartan medoxomil, The therapeutic efficacy of Indapamide can be increased when used in combination with Azilsartan medoxomil.]
[M03AA02, tubocurarine, The serum concentration of Indapamide can be increased when it is combined with Tubocurarine.]
[R03DX07, roflumilast, Indapamide may increase the excretion rate of Roflumilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FX04, ipilimumab, Indapamide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Vandetanib.]
[R02AA14, oxyquinoline, Indapamide may increase the excretion rate of Oxyquinoline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Indapamide.]
[J05AP03, boceprevir, The metabolism of Indapamide can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Indapamide can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Rilpivirine.]
[S01AA28, vancomycin, Indapamide may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Ezogabine.]
[B01AF01, rivaroxaban, Indapamide may increase the excretion rate of Rivaroxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Indacaterol.]
[C08DA01, verapamil, The metabolism of Indapamide can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Indapamide can be decreased when combined with Viloxazine.]
[C04AX07, vincamine, The therapeutic efficacy of Indapamide can be increased when used in combination with Vincamine.]
[B03BA01, vitamin B12, Indapamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA03, warfarin, Indapamide may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[S01AA13, fusidic acid, The metabolism of Indapamide can be decreased when combined with Fusidic acid.]
[N01AX15, xenon, Xenon may decrease the antihypertensive activities of Indapamide.]
[C03BA10, xipamide, The therapeutic efficacy of Indapamide can be increased when used in combination with Xipamide.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Indapamide can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Indapamide.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[M05BA05, tiludronic acid, Indapamide may increase the excretion rate of Tiludronic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[B06AC02, icatibant, Indapamide may increase the excretion rate of Icatibant which could result in a lower serum level and potentially a reduction in efficacy.]
[L01ED01, crizotinib, The metabolism of Indapamide can be decreased when combined with Crizotinib.]
[A02BC04, rabeprazole, Indapamide may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[H05BX03, doxercalciferol, The risk or severity of hypokalemia can be increased when Doxercalciferol is combined with Indapamide.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Indapamide.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Indapamide may increase the excretion rate of Deferiprone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[L01EJ01, ruxolitinib, Indapamide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Tolterodine.]
[J01DH04, doripenem, Indapamide may increase the excretion rate of Doripenem which could result in a lower serum level and potentially a reduction in efficacy.]
[A11CC03, alfacalcidol, The risk or severity of hypokalemia can be increased when Alfacalcidol is combined with Indapamide.]
[L01FA01, rituximab, Indapamide may increase the hypotensive activities of Rituximab.]
[J02AC03, voriconazole, The metabolism of Indapamide can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The serum concentration of Indapamide can be increased when it is combined with Atracurium.]
[S01FA01, atropine, Atropine may decrease the antihypertensive activities of Indapamide.]
[M01CB03, auranofin, Indapamide may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB11, prednylidene, Prednylidene may increase the hypokalemic activities of Indapamide.]
[B03XA04, peginesatide, Indapamide may increase the excretion rate of Peginesatide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC07, azacitidine, Indapamide may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX01, azathioprine, Indapamide may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC05, gemcitabine, Indapamide may increase the excretion rate of Gemcitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DF01, aztreonam, Indapamide may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Indapamide.]
[M03BX01, baclofen, The risk or severity of adverse effects can be increased when Baclofen is combined with Indapamide.]
[A08AA11, lorcaserin, Indapamide may increase the excretion rate of Lorcaserin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Indapamide can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Indapamide can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Indapamide can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The risk or severity of adverse effects can be increased when Indapamide is combined with Linaclotide.]
[C01CA18, octopamine, Octopamine may decrease the antihypertensive activities of Indapamide.]
[H02AA01, aldosterone, Aldosterone may increase the hypokalemic activities of Indapamide.]
[N05CA04, barbital, The risk or severity of hypotension and orthostatic hypotension can be increased when Barbital is combined with Indapamide.]
[C01AA01, acetyldigitoxin, The risk or severity of adverse effects can be increased when Indapamide is combined with Acetyldigitoxin.]
[D02BA02, octinoxate, Indapamide may increase the excretion rate of Octinoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE04, nelfinavir, The metabolism of Indapamide can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the antihypertensive activities of Indapamide.]
[N04BD02, rasagiline, Rasagiline may increase the hypotensive activities of Indapamide.]
[C08CA13, lercanidipine, The therapeutic efficacy of Indapamide can be increased when used in combination with Lercanidipine.]
[N02CC03, zolmitriptan, Zolmitriptan may decrease the antihypertensive activities of Indapamide.]
[R06AC06, thonzylamine, The serum concentration of Indapamide can be increased when it is combined with Thonzylamine.]
[G04BD10, darifenacin, The serum concentration of Indapamide can be increased when it is combined with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Indapamide may increase the excretion rate of Fludeoxyglucose (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AA01, ethyl ether, Diethyl ether may decrease the antihypertensive activities of Indapamide.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Pasireotide.]
[G04BE03, sildenafil, Sildenafil may increase the antihypertensive activities of Indapamide.]
[V08CA11, gadofosveset, Indapamide may increase the excretion rate of Gadofosveset trisodium which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX08, teduglutide, Indapamide may increase the excretion rate of Teduglutide which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Bencyclane.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Indapamide.]
[A16AX09, glycerol phenylbutyrate, Indapamide may increase the excretion rate of Glycerol phenylbutyrate which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Indapamide can be increased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, Indapamide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA10, benorilate, The therapeutic efficacy of Indapamide can be decreased when used in combination with Benorilate.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Indapamide.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Moxifloxacin.]
[A06AX06, tegaserod, The risk or severity of adverse effects can be increased when Indapamide is combined with Tegaserod.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Indapamide is combined with Insulin detemir.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Indapamide.]
[L03AA12, ancestim, Indapamide may increase the excretion rate of Ancestim which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH01, celecoxib, The therapeutic efficacy of Indapamide can be decreased when used in combination with Celecoxib.]
[N02CC02, naratriptan, Naratriptan may decrease the antihypertensive activities of Indapamide.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Indapamide.]
[L01EC02, dabrafenib, The serum concentration of Indapamide can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Benzydamine.]
[L01EE01, trametinib, Indapamide may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX05, florbetapir F-18, Indapamide may increase the excretion rate of Florbetapir (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX28, levomilnacipran, The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Indapamide.]
[C08EA02, bepridil, The therapeutic efficacy of Indapamide can be increased when used in combination with Bepridil.]
[C02KX05, riociguat, The therapeutic efficacy of Indapamide can be increased when used in combination with Riociguat.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Indapamide.]
[C02KX04, macitentan, The therapeutic efficacy of Indapamide can be increased when used in combination with Macitentan.]
[N06AX26, vortioxetine, Indapamide may increase the excretion rate of Vortioxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[G03AC08, etonogestrel, Indapamide may increase the excretion rate of Etonogestrel which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP05, simeprevir, The metabolism of Indapamide can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Indapamide may increase the excretion rate of Sofosbuvir which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Indapamide.]
[C01CA27, droxidopa, Indapamide may increase the excretion rate of Droxidopa which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB04, acebutolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Acebutolol.]
[N05CH03, tasimelteon, Indapamide may increase the excretion rate of Tasimelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AA07, metreleptin, The metabolism of Indapamide can be increased when combined with Metreleptin.]
[L04AA32, apremilast, Indapamide may increase the excretion rate of Apremilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BG02, formestane, Indapamide may increase the excretion rate of Formestane which could result in a lower serum level and potentially a reduction in efficacy.]
[S03BA03, betamethasone, Betamethasone may increase the hypokalemic activities of Indapamide.]
[S01ED02, betaxolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Betaxolol.]
[V03AB34, fomepizole, Indapamide may increase the excretion rate of Fomepizole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02CC01, bethanidine, The therapeutic efficacy of Indapamide can be increased when used in combination with Bethanidine.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Indapamide.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Indapamide.]
[A10BK03, empagliflozin, Empagliflozin may increase the diuretic activities of Indapamide.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Olodaterol.]
[V08AA01, diatrizoic acid, Indapamide may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EE02, unoprostone, The therapeutic efficacy of Indapamide can be increased when used in combination with Unoprostone.]
[D11AA01, glycopyrronium, The serum concentration of Indapamide can be increased when it is combined with Glycopyrronium.]
[V08AA04, iothalamic acid, Indapamide may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Eliglustat.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[N05AA04, acepromazine, Acepromazine may decrease the antihypertensive activities of Indapamide.]
[A06AB04, phenolphthalein, The risk or severity of adverse effects can be increased when Indapamide is combined with Phenolphthalein.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Indapamide.]
[A06AH03, naloxegol, The therapeutic efficacy of Indapamide can be decreased when used in combination with Naloxegol.]
[N04AA02, biperiden, The serum concentration of Indapamide can be increased when it is combined with Biperiden.]
[A06AG02, bisacodyl, The risk or severity of adverse effects can be increased when Indapamide is combined with Bisacodyl.]
[S03AA06, gentamicin, Indapamide may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AF03, edoxaban, Indapamide may increase the excretion rate of Edoxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Indapamide.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Panobinostat.]
[N02BE01, acetaminophen, Indapamide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DC01, bleomycin, Indapamide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AA09, difemerine, The serum concentration of Indapamide can be increased when it is combined with Difemerine.]
[C01EB17, ivabradine, The risk or severity of Cardiac Arrhythmia can be increased when Indapamide is combined with Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[A07DA06, eluxadoline, The therapeutic efficacy of Indapamide can be decreased when used in combination with Eluxadoline.]
[N05AX16, brexpiprazole, Brexpiprazole may decrease the antihypertensive activities of Indapamide.]
[G02CX02, flibanserin, Flibanserin may decrease the antihypertensive activities of Indapamide.]
[A06AD03, magnesium peroxide, The risk or severity of adverse effects can be increased when Indapamide is combined with Magnesium peroxide.]
[N05AX15, cariprazine, Cariprazine may decrease the antihypertensive activities of Indapamide.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Indapamide.]
[M02AA25, aceclofenac, The therapeutic efficacy of Indapamide can be decreased when used in combination with Aceclofenac.]
[M01AB11, acemetacin, The therapeutic efficacy of Indapamide can be decreased when used in combination with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Indapamide is combined with Insulin degludec.]
[V03AB37, idarucizumab, Indapamide may increase the excretion rate of Idarucizumab which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AC05, isavuconazole, The metabolism of Indapamide can be decreased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Indapamide.]
[L01XG03, ixazomib, Indapamide may increase the excretion rate of Ixazomib which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC27, selexipag, The therapeutic efficacy of Indapamide can be increased when used in combination with Selexipag.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Indapamide.]
[G04CA01, alfuzosin, Alfuzosin may increase the hypotensive activities of Indapamide.]
[M04AB05, lesinurad, Indapamide may increase the excretion rate of Lesinurad which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA05, aprobarbital, The serum concentration of Indapamide can be increased when it is combined with Aprobarbital.]
[M01AE16, alminoprofen, The therapeutic efficacy of Indapamide can be decreased when used in combination with Alminoprofen.]
[N03AX23, brivaracetam, Indapamide may increase the excretion rate of Brivaracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX52, venetoclax, The metabolism of Indapamide can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, Indapamide may increase the excretion rate of Bromazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Indapamide.]
[A02AD05, aluminum magnesium silicate, Indapamide may increase the excretion rate of Almasilate which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Indapamide.]
[N06AA19, amineptin, Amineptine may decrease the antihypertensive activities of Indapamide.]
[C03CA02, bumetanide, Indapamide may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Indapamide.]
[C07AA19, bupranolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Bupranolol.]
[N07BC01, buprenorphine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Buserelin.]
[N05BE01, buspirone, Indapamide may increase the excretion rate of Buspirone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Artemether.]
[M02AA03, clofezone, Indapamide may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AF01, butorphanol, The therapeutic efficacy of Indapamide can be decreased when used in combination with Butorphanol.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Indapamide.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Azithromycin.]
[A06AX07, plecanatide, The risk or severity of adverse effects can be increased when Indapamide is combined with Plecanatide.]
[L01EF02, ribociclib, The metabolism of Indapamide can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The therapeutic efficacy of Indapamide can be decreased when used in combination with Balsalazide.]
[R03CC12, bambuterol, Bambuterol may decrease the antihypertensive activities of Indapamide.]
[A06AH05, naldemedine, Indapamide may increase the excretion rate of Naldemedine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Indapamide.]
[C09AA07, benazepril, The therapeutic efficacy of Indapamide can be increased when used in combination with Benazepril.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Indapamide.]
[H05BX05, calcifediol, The risk or severity of hypokalemia can be increased when Calcifediol is combined with Indapamide.]
[D05AX03, calcitriol, The risk or severity of hypokalemia can be increased when Calcitriol is combined with Indapamide.]
[A12AA04, calcium carbonate, Indapamide may decrease the excretion rate of Calcium carbonate which could result in a higher serum level.]
[P01CA02, benznidazole, Indapamide may increase the excretion rate of Benznidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BA03, calcium chloride, Indapamide may decrease the excretion rate of Calcium chloride which could result in a higher serum level.]
[J01XX08, linezolid, Linezolid may increase the hypotensive activities of Indapamide.]
[J05AF06, abacavir, Indapamide may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE09, tipranavir, The metabolism of Indapamide can be decreased when combined with Tipranavir.]
[D11AX03, calcium gluconate, Indapamide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.]
[N07XX13, valbenazine, Indapamide may increase the excretion rate of Valbenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[A12AA01, calcium phosphate, Indapamide may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.]
[L01EX10, midostaurin, The metabolism of Indapamide can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, Safinamide may increase the hypotensive activities of Indapamide.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Delafloxacin.]
[L01BC06, capecitabine, Indapamide may increase the excretion rate of Capecitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Vorinostat.]
[C07AB07, bisoprolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Bisoprolol.]
[R03AC17, bitolterol, Bitolterol may decrease the antihypertensive activities of Indapamide.]
[J05AG03, efavirenz, The metabolism of Indapamide can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[N04AA11, bornaprine, The serum concentration of Indapamide can be increased when it is combined with Bornaprine.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Indapamide is combined with Nesiritide.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Budesonide may increase the hypokalemic activities of Indapamide.]
[C04AX20, buflomedil, Buflomedil may decrease the antihypertensive activities of Indapamide.]
[M01AB07, bumadizone, The therapeutic efficacy of Indapamide can be decreased when used in combination with Bumadizone.]
[N05CA03, butobarbital, The serum concentration of Indapamide can be increased when it is combined with Butobarbital.]
[N06AA15, butriptyline, Butriptyline may decrease the antihypertensive activities of Indapamide.]
[C01AA02, acetyldigoxins, The risk or severity of adverse effects can be increased when Indapamide is combined with Acetyldigoxin.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Indapamide.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Indapamide.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Acrivastine.]
[C09AA01, captopril, The therapeutic efficacy of Indapamide can be increased when used in combination with Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Indapamide can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Indapamide is combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, Indapamide may decrease the excretion rate of Calcium polycarbophil which could result in a higher serum level.]
[A03AA03, camylofine, The serum concentration of Indapamide can be increased when it is combined with Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Carbinoxamine.]
[C07AG02, carvedilol, The therapeutic efficacy of Indapamide can be increased when used in combination with Carvedilol.]
[B02BX09, fostamatinib, Fostamatinib may increase the antihypertensive activities of Indapamide.]
[N03AX24, cannabidiol, Cannabidiol may decrease the antihypertensive activities of Indapamide.]
[L04AA37, baricitinib, Indapamide may increase the excretion rate of Baricitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Encorafenib.]
[J01DD14, ceftibuten, Indapamide may increase the excretion rate of Ceftibuten which could result in a lower serum level and potentially a reduction in efficacy.]
[J01GB14, plazomicin, Indapamide may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Indapamide can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Indapamide may increase the excretion rate of Migalastat which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX17, stiripentol, The metabolism of Indapamide can be decreased when combined with Stiripentol.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Indapamide.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Indapamide.]
[N01BA04, chloroprocaine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Chloroprocaine.]
[D08AE05, chloroxylenol, Indapamide may increase the excretion rate of Chloroxylenol which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA06, chlorphenoxamine, The serum concentration of Indapamide can be increased when it is combined with Chlorphenoxamine.]
[M01AC05, lornoxicam, The therapeutic efficacy of Indapamide can be decreased when used in combination with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Inotersen.]
[R03BB08, revefenacin, The serum concentration of Indapamide can be increased when it is combined with Revefenacin.]
[L01AD01, carmustine, Indapamide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Amifampridine.]
[A06AX05, prucalopride, The risk or severity of adverse effects can be increased when Indapamide is combined with Prucalopride.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Cibenzoline.]
[C09AA08, cilazapril, The therapeutic efficacy of Indapamide can be increased when used in combination with Cilazapril.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Cilostazol.]
[A03FA08, cinitapride, Cinitapride may decrease the antihypertensive activities of Indapamide.]
[S01ED05, carteolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Carteolol.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Triclabendazole.]
[L04AA42, siponimod, Siponimod may decrease the antihypertensive activities of Indapamide.]
[J01FA09, clarithromycin, The metabolism of Indapamide can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, Indapamide may increase the excretion rate of Solriamfetol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA09, clobazam, Indapamide may increase the excretion rate of Clobazam which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB14, cloprednol, Cloprednol may increase the hypokalemic activities of Indapamide.]
[A06AB05, castor oil, The risk or severity of adverse effects can be increased when Indapamide is combined with Castor oil.]
[V03AE07, calcium acetate, Indapamide may decrease the excretion rate of Calcium acetate which could result in a higher serum level.]
[C09CA06, candesartan, The therapeutic efficacy of Indapamide can be increased when used in combination with Candesartan.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB17, cortivazol, Cortivazol may increase the hypokalemic activities of Indapamide.]
[J01DC04, cefaclor, Indapamide may increase the excretion rate of Cefaclor which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB05, cefadroxil, Indapamide may increase the excretion rate of Cefadroxil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DC05, cefotetan, Indapamide may increase the excretion rate of Cefotetan which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DD02, ceftazidime, Indapamide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BX03, cicletanine, The therapeutic efficacy of Indapamide can be increased when used in combination with Cicletanine.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DD04, ceftriaxone, Indapamide may increase the excretion rate of Ceftriaxone which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Indapamide can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Indapamide.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Indapamide can be increased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, Yohimbine may decrease the antihypertensive activities of Indapamide.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Indapamide is combined with Insulin pork.]
[A06AB03, danthron, The risk or severity of adverse effects can be increased when Indapamide is combined with Dantron.]
[J01XX09, daptomycin, Indapamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB01, cephalexin, Indapamide may increase the excretion rate of Cephalexin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01DB09, cephradine, Indapamide may increase the excretion rate of Cefradine which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB13, deflazacort, Deflazacort may increase the hypokalemic activities of Indapamide.]
[N03AX25, cenobamate, The serum concentration of Indapamide can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[M09AX08, golodirsen, Indapamide may increase the excretion rate of Golodirsen which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Indapamide.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, The risk or severity of hypokalemia can be increased when Dexpanthenol is combined with Indapamide.]
[N02AX03, dezocine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Dezocine.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Gatifloxacin.]
[J05AE05, amprenavir, The metabolism of Indapamide can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, Frovatriptan may decrease the antihypertensive activities of Indapamide.]
[G04CB02, dutasteride, Dutasteride may decrease the antihypertensive activities of Indapamide.]
[R02AA03, dichlorobenzyl alcohol, Indapamide may increase the excretion rate of Dichlorobenzyl alcohol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03DB08, dienogest, Indapamide may increase the excretion rate of Dienogest which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AA08, dihydrocodeine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Dihydrocodeine.]
[N02CC06, eletriptan, Eletriptan may decrease the antihypertensive activities of Indapamide.]
[M01AH02, rofecoxib, The therapeutic efficacy of Indapamide can be decreased when used in combination with Rofecoxib.]
[C08CA16, clevidipine, Indapamide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD07, dronedarone, The metabolism of Indapamide can be decreased when combined with Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Chlorcyclizine.]
[C02AA06, methoserpidine, The therapeutic efficacy of Indapamide can be increased when used in combination with Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Indapamide.]
[A03AA08, dihexyverine, The serum concentration of Indapamide can be increased when it is combined with Dihexyverine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Indapamide is combined with Opicapone.]
[C01CA14, dopexamine, Dopexamine may decrease the antihypertensive activities of Indapamide.]
[D07XB03, fluprednidene, Fluprednidene may increase the hypokalemic activities of Indapamide.]
[G04BD09, trospium, The serum concentration of Indapamide can be increased when it is combined with Trospium.]
[M01AC04, droxicam, The therapeutic efficacy of Indapamide can be decreased when used in combination with Droxicam.]
[V08CA05, mangafodipir, Indapamide may increase the excretion rate of Mangafodipir which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX22, selpercatinib, Selpercatinib may decrease the antihypertensive activities of Indapamide.]
[M02AA27, dexketoprofen, The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Indapamide.]
[C08CA17, levamlodipine, The therapeutic efficacy of Indapamide can be increased when used in combination with Levamlodipine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Fostemsavir.]
[L04AC19, satralizumab, The serum concentration of Indapamide can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Oliceridine.]
[P01BA01, chloroquine, Indapamide may increase the excretion rate of Chloroquine which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Indapamide can be increased when used in combination with Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, Indapamide may increase the excretion rate of Chlorpromazine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Indapamide.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Chlorprothixene.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Indapamide can be increased when used in combination with Chlorthalidone.]
[M03BB03, chlorzoxazone, Indapamide may increase the excretion rate of Chlorzoxazone which could result in a lower serum level and potentially a reduction in efficacy.]
[A11CC05, cholecalciferol, The risk or severity of hypokalemia can be increased when Cholecalciferol is combined with Indapamide.]
[N02BA07, ethenzamide, The therapeutic efficacy of Indapamide can be decreased when used in combination with Ethenzamide.]
[C10AC01, cholestyramine resin, Cholestyramine can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BA03, choline salicylate, Indapamide may increase the excretion rate of Choline salicylate which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB08, etodolac, The therapeutic efficacy of Indapamide can be decreased when used in combination with Etodolac.]
[M02AA06, etofenamate, The therapeutic efficacy of Indapamide can be decreased when used in combination with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Indapamide can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Indapamide can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Relugolix.]
[M01AX25, chondroitin sulfates, Indapamide may increase the excretion rate of Chondroitin sulfate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FX21, naxitamab, Naxitamab may decrease the antihypertensive activities of Indapamide.]
[P03AX07, abametapir, The serum concentration of Indapamide can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Indapamide is combined with Vericiguat.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Felbamate.]
[M01AE05, fenbufen, The therapeutic efficacy of Indapamide can be decreased when used in combination with Fenbufen.]
[C01CA19, fenoldopam, The therapeutic efficacy of Indapamide can be increased when used in combination with Fenoldopam.]
[N06BA08, fenozolone, Fenozolone may decrease the antihypertensive activities of Indapamide.]
[G04CB01, finasteride, Finasteride may decrease the antihypertensive activities of Indapamide.]
[J01DD15, cefdinir, Indapamide may increase the excretion rate of Cefdinir which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Flumequine.]
[R03BA03, flunisolide, Flunisolide may increase the hypokalemic activities of Indapamide.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may increase the hypokalemic activities of Indapamide.]
[N02BG07, flupirtine, Indapamide may increase the excretion rate of Flupirtine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Formoterol.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Indapamide is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Indapamide.]
[N01AB05, trichloroethylene, Trichloroethylene may decrease the antihypertensive activities of Indapamide.]
[H04AA02, dasiglucagon, The therapeutic efficacy of Indapamide can be increased when used in combination with Dasiglucagon.]
[A02BA01, cimetidine, Indapamide may increase the excretion rate of Cimetidine which could result in a lower serum level and potentially a reduction in efficacy.]
[V08CA04, gadoteridol, Indapamide may increase the excretion rate of Gadoteridol which could result in a lower serum level and potentially a reduction in efficacy.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Indapamide can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Indapamide can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Indapamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of hyponatremia can be increased when Citalopram is combined with Indapamide.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Indapamide is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Indapamide may increase the excretion rate of Ioflupane I-123 which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AA01, technetium Tc 99m exametazime, Indapamide may increase the excretion rate of Technetium Tc-99m exametazime which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX06, florbetaben f-18, Indapamide may increase the excretion rate of Florbetaben (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Clemastine.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Indapamide.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Indapamide.]
[R03CC13, clenbuterol, Clenbuterol may decrease the antihypertensive activities of Indapamide.]
[A12AA02, calcium glubionate, Indapamide may decrease the excretion rate of Calcium glubionate anhydrous which could result in a higher serum level.]
[N06AX25, St. John's wort extract, The metabolism of Indapamide can be increased when combined with St. John's Wort.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Clofazimine.]
[N01BB10, levobupivacaine, Indapamide may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Pacritinib.]
[N06AA04, clomipramine, Indapamide may increase the excretion rate of Clomipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AE01, clonazepam, Indapamide may increase the excretion rate of Clonazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EA04, clonidine, The risk or severity of hypotension can be increased when Clonidine is combined with Indapamide.]
[C01EB24, mavacamten, The serum concentration of Indapamide can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Indapamide may increase the excretion rate of Oseltamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Indapamide.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Granisetron.]
[N05AH02, clozapine, The metabolism of Indapamide can be decreased when combined with Clozapine.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Indapamide.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Indapamide.]
[J01GB12, arbekacin, Indapamide may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[H01AC08, somatrogon, The metabolism of Indapamide can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Cocaine.]
[C02KB01, metyrosine, The therapeutic efficacy of Indapamide can be increased when used in combination with Metyrosine.]
[M01AX13, proquazone, The therapeutic efficacy of Indapamide can be decreased when used in combination with Proquazone.]
[R05DA04, codeine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Codeine.]
[M03AC05, hexafluorenium, The serum concentration of Indapamide can be increased when it is combined with Hexafluronium.]
[M04AC01, colchicine, Indapamide may increase the excretion rate of Colchicine which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A03AB10, hexocyclium, The serum concentration of Indapamide can be increased when it is combined with Hexocyclium.]
[A03BB06, homatropine methylbromide, The serum concentration of Indapamide can be increased when it is combined with Homatropine methylbromide.]
[J01XB01, colistin, Indapamide may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Desflurane.]
[A04AA03, tropisetron, Indapamide may increase the excretion rate of Tropisetron which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX28, ifenprodil, Ifenprodil may decrease the antihypertensive activities of Indapamide.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be decreased when used in combination with Indapamide.]
[N02BA16, imidazole-2-hydroxybenzoate, The therapeutic efficacy of Indapamide can be decreased when used in combination with Imidazole salicylate.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Indapamide.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Indapamide is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Indapamide can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, Ciclesonide may increase the hypokalemic activities of Indapamide.]
[B01AC10, indobufen, The therapeutic efficacy of Indapamide can be decreased when used in combination with Indobufen.]
[R06AX27, desloratadine, The serum concentration of Indapamide can be increased when it is combined with Desloratadine.]
[J05AB14, valganciclovir, Indapamide may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C05BB03, invert sugar, Indapamide may increase the excretion rate of Invert sugar which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB09, iodixanol, Indapamide may increase the excretion rate of Iodixanol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB05, iopromide, Indapamide may increase the excretion rate of Iopromide which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB07, ioversol, Indapamide may increase the excretion rate of Ioversol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB12, ioxilan, Indapamide may increase the excretion rate of Ioxilan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH03, valdecoxib, The therapeutic efficacy of Indapamide can be decreased when used in combination with Valdecoxib.]
[C01AA06, lanatoside C, The risk or severity of adverse effects can be increased when Indapamide is combined with Lanatoside C.]
[A03AX10, isometheptene, Isometheptene may decrease the antihypertensive activities of Indapamide.]
[N02CC05, almotriptan, Indapamide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH04, parecoxib, The therapeutic efficacy of Indapamide can be decreased when used in combination with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Indapamide can be decreased when combined with Itraconazole.]
[S01AD03, acyclovir, Indapamide may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Emedastine.]
[N05BA10, ketazolam, Indapamide may increase the excretion rate of Ketazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AA06, kebuzone, The therapeutic efficacy of Indapamide can be decreased when used in combination with Kebuzone.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Indapamide can be decreased when combined with Posaconazole.]
[S01EE04, travoprost, The therapeutic efficacy of Indapamide can be increased when used in combination with Travoprost.]
[S01EE03, bimatoprost, The therapeutic efficacy of Indapamide can be increased when used in combination with Bimatoprost.]
[C08CA09, lacidipine, Indapamide may increase the hypotensive activities of Lacidipine.]
[A06AD12, lactitol, The risk or severity of adverse effects can be increased when Indapamide is combined with Lactitol.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Indapamide.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Levocabastine.]
[S01BA03, cortisone, Cortisone may increase the hypokalemic activities of Indapamide.]
[N07BC04, lofexidine, The therapeutic efficacy of Indapamide can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Lomefloxacin.]
[M01AB09, lonazolac, The therapeutic efficacy of Indapamide can be decreased when used in combination with Lonazolac.]
[M02AA31, loxoprofen, The therapeutic efficacy of Indapamide can be decreased when used in combination with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[C09AA03, lisinopril, The therapeutic efficacy of Indapamide can be increased when used in combination with Lisinopril.]
[A06AD01, magnesium carbonate, The risk or severity of adverse effects can be increased when Indapamide is combined with Magnesium carbonate.]
[C08CA11, manidipine, The therapeutic efficacy of Indapamide can be increased when used in combination with Manidipine.]
[A03AA04, mebeverine, The serum concentration of Indapamide can be increased when it is combined with Mebeverine.]
[A08AA09, mefenorex, Mefenorex may decrease the antihypertensive activities of Indapamide.]
[H02AB15, meprednisone, Meprednisone may increase the hypokalemic activities of Indapamide.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Mequitazine.]
[J01DH02, meropenem, Indapamide may increase the excretion rate of Meropenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Adenosine.]
[N04AA03, methixene, The serum concentration of Indapamide can be increased when it is combined with Metixene.]
[R03CB02, methoxyphenamine, Methoxyphenamine may decrease the antihypertensive activities of Indapamide.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Cyclizine.]
[C03DA04, eplerenone, The therapeutic efficacy of Indapamide can be increased when used in combination with Eplerenone.]
[N05AD03, metylperon, Indapamide may increase the excretion rate of Melperone which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Indapamide can be increased when used in combination with Cyclopenthiazide.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Indapamide.]
[J05AF07, tenofovir disoproxil, Indapamide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AA01, cyclophosphamide, The risk or severity of granulocytopenia can be increased when Indapamide is combined with Cyclophosphamide.]
[N06AX07, minaprine, Minaprine may increase the hypotensive activities of Indapamide.]
[S01XA18, cyclosporine, The risk or severity of renal failure can be increased when Indapamide is combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the hypotensive activities of Indapamide.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Indapamide.]
[C09AA13, moexipril, The therapeutic efficacy of Indapamide can be increased when used in combination with Moexipril.]
[M02AA02, mofebutazone, The therapeutic efficacy of Indapamide can be decreased when used in combination with Mofebutazone.]
[M01AX22, morniflumate, The therapeutic efficacy of Indapamide can be decreased when used in combination with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Indapamide can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The therapeutic efficacy of Indapamide can be increased when used in combination with Moxonidine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Vardenafil.]
[M01AH05, etoricoxib, The therapeutic efficacy of Indapamide can be decreased when used in combination with Etoricoxib.]
[L01AX04, dacarbazine, Indapamide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.]
[G03XA01, danazol, The metabolism of Indapamide can be decreased when combined with Danazol.]
[C02CC04, debrisoquin, The therapeutic efficacy of Indapamide can be increased when used in combination with Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Indapamide.]
[M01AX01, nabumetone, The therapeutic efficacy of Indapamide can be decreased when used in combination with Nabumetone.]
[N07BB05, nalmefene, Indapamide may increase the excretion rate of Nalmefene which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA15, potassium lactate, The risk or severity of adverse effects can be increased when Indapamide is combined with Potassium lactate.]
[C07AB12, nebivolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Nebivolol.]
[S01GX04, nedocromil, Indapamide may increase the excretion rate of Nedocromil which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX06, nefazodone, The metabolism of Indapamide can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, The therapeutic efficacy of Indapamide can be increased when used in combination with Nicorandil.]
[L02BB02, nilutamide, Indapamide may increase the excretion rate of Nilutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA23, theodrenaline, The risk or severity of Cardiac Arrhythmia can be increased when Theodrenaline is combined with Indapamide.]
[M03AC11, cisatracurium, The serum concentration of Indapamide can be increased when it is combined with Cisatracurium.]
[C01CA05, norfenefrine, Norfenefrine may decrease the antihypertensive activities of Indapamide.]
[R05DA06, normethadone, The therapeutic efficacy of Indapamide can be decreased when used in combination with Normethadone.]
[B01AX05, fondaparinux, Indapamide may increase the excretion rate of Fondaparinux which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB10, escitalopram, The risk or severity of hyponatremia can be increased when Escitalopram is combined with Indapamide.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Solifenacin.]
[A07EC03, olsalazine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Olsalazine.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Desipramine.]
[C01AA07, deslanoside, The risk or severity of adverse effects can be increased when Indapamide is combined with Deslanoside.]
[H01BA02, desmopressin, Indapamide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.]
[D07XC02, desoximetasone, Desoximetasone may increase the hypokalemic activities of Indapamide.]
[V04CH02, indigo carmine, Indapamide may increase the excretion rate of Indigotindisulfonic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA03, desoxycorticosterone, Desoxycortone may increase the hypokalemic activities of Indapamide.]
[J01DH03, ertapenem, Indapamide may increase the excretion rate of Ertapenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C09XA02, aliskiren, The therapeutic efficacy of Indapamide can be increased when used in combination with Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The therapeutic efficacy of Indapamide can be decreased when used in combination with Oxaprozin.]
[N03AF02, oxcarbazepine, The risk or severity of hyponatremia can be increased when Indapamide is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Indapamide can be increased when combined with Dexamethasone.]
[N04AA08, dexetimide, The serum concentration of Indapamide can be increased when it is combined with Dexetimide.]
[G04BD04, oxybutynin, The serum concentration of Indapamide can be increased when it is combined with Oxybutynin.]
[A03AA01, oxyphencyclimine, The serum concentration of Indapamide can be increased when it is combined with Oxyphencyclimine.]
[N06BA02, dextroamphetamine, Indapamide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[R05DA09, dextromethorphan, The serum concentration of Indapamide can be increased when it is combined with Dextromethorphan.]
[N02AC01, dextromoramide, The therapeutic efficacy of Indapamide can be decreased when used in combination with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of hyponatremia can be increased when Paroxetine is combined with Indapamide.]
[N07BC06, heroin, The therapeutic efficacy of Indapamide can be decreased when used in combination with Diamorphine.]
[P03AC04, permethrin, Indapamide may increase the excretion rate of Permethrin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, Indapamide may increase the excretion rate of Diazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AH01, diazoxide, Diazoxide may increase the hypotensive activities of Indapamide.]
[N06AA08, dibenzepin, Dibenzepin may decrease the antihypertensive activities of Indapamide.]
[R05DA08, pholcodine, Indapamide may increase the excretion rate of Pholcodine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The therapeutic efficacy of Indapamide can be decreased when used in combination with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Indapamide.]
[A03AA07, dicyclomine, Indapamide may increase the excretion rate of Dicyclomine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF02, didanosine, Indapamide may increase the excretion rate of Didanosine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DG01, pinacidil, The therapeutic efficacy of Indapamide can be increased when used in combination with Pinacidil.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Pinaverium.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Indapamide.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Indapamide is combined with Pipamperone.]
[A03AB14, pipenzolate, The serum concentration of Indapamide can be increased when it is combined with Pipenzolate.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Erlotinib.]
[R03CC07, pirbuterol, Pirbuterol may decrease the antihypertensive activities of Indapamide.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, Diethylpropion may decrease the antihypertensive activities of Indapamide.]
[C08CA03, isradipine, The therapeutic efficacy of Indapamide can be increased when used in combination with Isradipine.]
[D07XC04, diflucortolone, Difluocortolone may increase the hypokalemic activities of Indapamide.]
[A03AB11, poldine, The serum concentration of Indapamide can be increased when it is combined with Poldine.]
[N02BA11, diflunisal, The therapeutic efficacy of Indapamide can be decreased when used in combination with Diflunisal.]
[C01AA04, digitoxin, The risk or severity of adverse effects can be increased when Indapamide is combined with Digitoxin.]
[C01AA05, digoxin, Indapamide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, The therapeutic efficacy of Indapamide can be increased when used in combination with Dihydralazine.]
[C04AE04, dihydroergocristine, Dihydroergocristine may decrease the antihypertensive activities of Indapamide.]
[N02CA01, dihydroergotamine, Dihydroergotamine may decrease the antihypertensive activities of Indapamide.]
[N02AA03, hydromorphone, Indapamide may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX04, lenalidomide, Indapamide may increase the excretion rate of Lenalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[A11CC02, dihydrotachysterol, The risk or severity of hypokalemia can be increased when Dihydrotachysterol is combined with Indapamide.]
[J05AE08, atazanavir, The metabolism of Indapamide can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The therapeutic efficacy of Indapamide can be increased when used in combination with Treprostinil.]
[H03BC01, potassium perchlorate, Indapamide may increase the excretion rate of Potassium perchlorate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB04, pralidoxime, Indapamide may increase the excretion rate of Pralidoxime which could result in a lower serum level and potentially a reduction in efficacy.]
[C08DB01, diltiazem, The therapeutic efficacy of Indapamide can be increased when used in combination with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Indapamide may increase the excretion rate of Dimercaprol which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB03, dimethindene, The serum concentration of Indapamide can be increased when it is combined with Dimetindene.]
[R03CC08, procaterol, Procaterol may decrease the antihypertensive activities of Indapamide.]
[M02AX03, dimethyl sulfoxide, Indapamide may increase the excretion rate of Dimethyl sulfoxide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, The therapeutic efficacy of Indapamide can be decreased when used in combination with Propyphenazone.]
[M01AB14, proglumetacin, The therapeutic efficacy of Indapamide can be decreased when used in combination with Proglumetacin.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The therapeutic efficacy of Indapamide can be decreased when used in combination with Diphenoxylate.]
[C09AA06, quinapril, The therapeutic efficacy of Indapamide can be increased when used in combination with Quinapril.]
[B01AC07, dipyridamole, Dipyridamole may increase the antihypertensive activities of Indapamide.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may decrease the antihypertensive activities of Indapamide.]
[N06AA23, quinupramine, Quinupramine may decrease the antihypertensive activities of Indapamide.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Cisapride.]
[C09AA05, ramipril, The therapeutic efficacy of Indapamide can be increased when used in combination with Ramipril.]
[R03CC14, reproterol, Reproterol may decrease the antihypertensive activities of Indapamide.]
[S01AX06, resorcinol, Indapamide may increase the excretion rate of Resorcinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA03, disopyramide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Indapamide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Indapamide can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Indapamide can be increased when combined with Rifapentine.]
[N05AX08, risperidone, Indapamide may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Levocetirizine.]
[N01BB09, ropivacaine, Indapamide may increase the excretion rate of Ropivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Rosoxacin.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Indapamide.]
[A04AD12, aprepitant, The metabolism of Indapamide can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Indapamide.]
[G04BE08, tadalafil, The therapeutic efficacy of Indapamide can be increased when used in combination with Tadalafil.]
[S01BC05, ketorolac, The therapeutic efficacy of Indapamide can be decreased when used in combination with Ketorolac.]
[C02KX02, ambrisentan, The therapeutic efficacy of Indapamide can be increased when used in combination with Ambrisentan.]
[C01EB18, ranolazine, Indapamide may increase the excretion rate of Ranolazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA06, salsalate, The therapeutic efficacy of Indapamide can be decreased when used in combination with Salsalate.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Salmeterol.]
[H05BA01, salmon calcitonin, Indapamide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA07, dobutamine, Indapamide may increase the excretion rate of Dobutamine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Domperidone.]
[C01CA04, dopamine, Indapamide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Dosulepin.]
[R07AB01, doxapram, Doxapram may decrease the antihypertensive activities of Indapamide.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Doxepin.]
[A06AB06, sennosides, USP, The risk or severity of adverse effects can be increased when Indapamide is combined with Sennosides.]
[J01AA02, doxycycline, Indapamide may increase the excretion rate of Doxycycline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Indapamide.]
[N06AB06, sertraline, The risk or severity of hyponatremia can be increased when Sertraline is combined with Indapamide.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may decrease the antihypertensive activities of Indapamide.]
[A08AA10, sibutramine, The risk or severity of hyponatremia can be increased when Sibutramine is combined with Indapamide.]
[V03AG05, sodium phosphate, Indapamide may increase the nephrotoxic activities of Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, The risk or severity of adverse effects can be increased when Indapamide is combined with Sodium sulfate.]
[C09AA11, spirapril, The therapeutic efficacy of Indapamide can be increased when used in combination with Spirapril.]
[R03DA01, dyphylline, Indapamide may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Sultopride.]
[N02CC01, sumatriptan, Indapamide may increase the excretion rate of Sumatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX07, edrophonium, Indapamide may increase the excretion rate of Edrophonium which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB13, talinolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Talinolol.]
[H01AA01, corticotropin, Corticotropin may increase the hypokalemic activities of Indapamide.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Temafloxacin.]
[L01AX03, temozolomide, Indapamide may increase the excretion rate of Temozolomide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC02, tenoxicam, The therapeutic efficacy of Indapamide can be decreased when used in combination with Tenoxicam.]
[G04CA03, terazosin, The therapeutic efficacy of Indapamide can be increased when used in combination with Terazosin.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Terodiline.]
[S01GA02, tetrahydrozoline, Tetryzoline may decrease the antihypertensive activities of Indapamide.]
[G04BD01, emepronium, The serum concentration of Indapamide can be increased when it is combined with Emepronium.]
[N06AX14, tianeptine, Tianeptine may decrease the antihypertensive activities of Indapamide.]
[C09AA02, enalapril, The therapeutic efficacy of Indapamide can be increased when used in combination with Enalapril.]
[M01AG02, tolfenamic acid, The therapeutic efficacy of Indapamide can be decreased when used in combination with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the hypotensive activities of Indapamide.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Indapamide.]
[N03AX11, topiramate, The risk or severity of hypokalemia can be increased when Indapamide is combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of hypercalcemia can be increased when Indapamide is combined with Toremifene.]
[C03CA04, torsemide, The therapeutic efficacy of Indapamide can be increased when used in combination with Torasemide.]
[R01AA09, tramazoline, Tramazoline may decrease the antihypertensive activities of Indapamide.]
[C09AA10, trandolapril, The therapeutic efficacy of Indapamide can be increased when used in combination with Trandolapril.]
[N05CC01, chloral hydrate, Indapamide may increase the excretion rate of Chloral hydrate which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB08, tridihexethyl, The serum concentration of Indapamide can be increased when it is combined with Tridihexethyl.]
[H02CA01, trilostane, Trilostane may increase the hypokalemic activities of Indapamide.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Triptorelin.]
[N04AA12, tropatepine, The serum concentration of Indapamide can be increased when it is combined with Tropatepine.]
[R03CC11, tulobuterol, Tulobuterol may decrease the antihypertensive activities of Indapamide.]
[C02CA06, urapidil, The therapeutic efficacy of Indapamide can be increased when used in combination with Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Indapamide.]
[S01FB02, ephedrine, The risk or severity of Cardiac Arrhythmia can be increased when Ephedrine is combined with Indapamide.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Indapamide.]
[N06AX16, venlafaxine, Indapamide may increase the excretion rate of Venlafaxine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CX07, xamoterol, Xamoterol may decrease the antihypertensive activities of Indapamide.]
[S01GA03, xylometazoline, Xylometazoline may decrease the antihypertensive activities of Indapamide.]
[C08CA12, mepirodipine, Indapamide may increase the antihypertensive activities of Barnidipine.]
[S01EA01, epinephrine, The risk or severity of Cardiac Arrhythmia can be increased when Epinephrine is combined with Indapamide.]
[C09AA15, zofenopril, The therapeutic efficacy of Indapamide can be increased when used in combination with Zofenopril.]
[M01AB04, zomepirac, The therapeutic efficacy of Indapamide can be decreased when used in combination with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Indapamide is combined with Insulin glulisine.]
[L01XA02, carboplatin, Indapamide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC02, guanfacine, The therapeutic efficacy of Indapamide can be increased when used in combination with Guanfacine.]
[B01AC11, iloprost, Iloprost may increase the hypotensive activities of Indapamide.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Indapamide.]
[A11CC01, ergocalciferol, The risk or severity of hypokalemia can be increased when Ergocalciferol is combined with Indapamide.]
[G02AB03, ergonovine, Ergometrine may decrease the antihypertensive activities of Indapamide.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may decrease the antihypertensive activities of Indapamide.]
[N02CA02, ergotamine, The metabolism of Indapamide can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Valproic acid.]
[L03AX05, pidotimod, Indapamide may increase the excretion rate of Pidotimod which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA17, erythromycin, The metabolism of Indapamide can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Indapamide may increase the excretion rate of Estazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC02, pantoprazole, Indapamide may increase the excretion rate of Pantoprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA03, estradiol, Indapamide may increase the excretion rate of Estradiol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA57, estrogens, conjugated (USP), Indapamide may increase the excretion rate of Conjugated estrogens which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK02, ethambutol, Indapamide may increase the excretion rate of Ethambutol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA05, fluticasone, Fluticasone may increase the hypokalemic activities of Indapamide.]
[V08CA03, gadodiamide, Indapamide may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA15, gepefrine, Gepefrine may decrease the antihypertensive activities of Indapamide.]
[V03AF05, amifostine, Indapamide may increase the hypotensive activities of Amifostine.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Ibutilide.]
[N04AA05, profenamine, The serum concentration of Indapamide can be increased when it is combined with Profenamine.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Indapamide.]
[M01AC06, meloxicam, The therapeutic efficacy of Indapamide can be decreased when used in combination with Meloxicam.]
[S01XA06, ethylmorphine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Ethylmorphine.]
[C01CA01, etilefrine, Etilefrine may decrease the antihypertensive activities of Indapamide.]
[N01AX07, etomidate, Indapamide may increase the excretion rate of Etomidate which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Tacrolimus.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Fleroxacin.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Astemizole.]
[R06AX12, terfenadine, The metabolism of Indapamide can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Indapamide may increase the excretion rate of Trimetrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX12, bupropion, Indapamide may increase the excretion rate of Bupropion which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB08, fluvoxamine, The risk or severity of hyponatremia can be increased when Fluvoxamine is combined with Indapamide.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Encainide.]
[L02AE02, leuprolide, Indapamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01CB01, gold sodium thiomalate, Indapamide may increase the excretion rate of Sodium aurothiomalate which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, Indapamide may increase the excretion rate of Dextran which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AF02, dexrazoxane, Indapamide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Famotidine.]
[A16AA01, levocarnitine, Indapamide may increase the excretion rate of Levocarnitine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA02, felodipine, The therapeutic efficacy of Indapamide can be increased when used in combination with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Fendiline.]
[M01AE04, fenoprofen, The therapeutic efficacy of Indapamide can be decreased when used in combination with Fenoprofen.]
[R03CC04, fenoterol, Fenoterol may decrease the antihypertensive activities of Indapamide.]
[N02AB03, fentanyl, Indapamide may increase the excretion rate of Fentanyl which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Salbutamol.]
[L01BB06, clofarabine, Indapamide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07AX03, cevimeline, Indapamide may increase the excretion rate of Cevimeline which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD02, flavoxate, Indapamide may increase the excretion rate of Flavoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Flecainide.]
[N02BG04, floctafenine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Indapamide can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Indapamide may increase the excretion rate of Flucytosine which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA02, fludrocortisone, Fludrocortisone may increase the hypokalemic activities of Indapamide.]
[V03AB25, flumazenil, Indapamide may increase the excretion rate of Flumazenil which could result in a lower serum level and potentially a reduction in efficacy.]
[D07XB01, flumethasone, Flumethasone may increase the hypokalemic activities of Indapamide.]
[D07AC08, fluocinonide, Fluocinonide may increase the hypokalemic activities of Indapamide.]
[N06AA14, melitracen, Melitracen may decrease the antihypertensive activities of Indapamide.]
[H02AB03, fluocortolone, Fluocortolone may increase the hypokalemic activities of Indapamide.]
[V03AZ01, ethanol, The risk or severity of hypotension and orthostatic hypotension can be increased when Ethanol is combined with Indapamide.]
[L01BC09, floxuridine, Indapamide may increase the excretion rate of Floxuridine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01CB05, fluorometholone, Fluorometholone may increase the hypokalemic activities of Indapamide.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Indapamide.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Flupentixol.]
[N05CD01, flurazepam, Indapamide may increase the excretion rate of Flurazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC04, flurbiprofen, The therapeutic efficacy of Indapamide can be decreased when used in combination with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Fluspirilene.]
[L02BB01, flutamide, Indapamide may increase the excretion rate of Flutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX02, folic acid, Indapamide may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[S02AA17, fosfomycin, Indapamide may increase the excretion rate of Fosfomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[L01BC03, tegafur, Indapamide may increase the excretion rate of Tegafur which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX17, adrafinil, Adrafinil may decrease the antihypertensive activities of Indapamide.]
[M03AA01, alcuronium, The serum concentration of Indapamide can be increased when it is combined with Alcuronium.]
[G01AX06, furazolidone, Furazolidone may increase the hypotensive activities of Indapamide.]
[J05AE10, darunavir, The metabolism of Indapamide can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The therapeutic efficacy of Indapamide can be increased when used in combination with Furosemide.]
[N05CF04, eszopiclone, Indapamide may increase the excretion rate of Eszopiclone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Indapamide.]
[M03AC02, gallamine, The serum concentration of Indapamide can be increased when it is combined with Gallamine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Gallopamil.]
[S01AD09, ganciclovir, Indapamide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA04, barbexaclone, The risk or severity of hypotension and orthostatic hypotension can be increased when Barbexaclone is combined with Indapamide.]
[C10AB04, gemfibrozil, Indapamide may increase the excretion rate of Gemfibrozil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XA03, telavancin, Indapamide may increase the excretion rate of Telavancin which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Dasatinib.]
[N04BC06, cabergoline, Cabergoline may decrease the antihypertensive activities of Indapamide.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Indapamide.]
[A12AA13, calcium citrate, Indapamide may decrease the excretion rate of Calcium citrate which could result in a higher serum level.]
[A12AA10, calcium gluceptate, Indapamide may decrease the excretion rate of Calcium glucoheptonate which could result in a higher serum level.]
[A12AA05, calcium lactate, Indapamide may decrease the excretion rate of Calcium lactate which could result in a higher serum level.]
[A12AA30, calcium levulinate, Indapamide may decrease the excretion rate of Calcium levulinate which could result in a higher serum level.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Methsuximide.]
[N01AH02, alfentanil, The therapeutic efficacy of Indapamide can be decreased when used in combination with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Lapatinib.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Indapamide.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Indapamide.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Indapamide.]
[N05CM18, dexmedetomidine, Indapamide may increase the excretion rate of Dexmedetomidine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX01, glycerin, The risk or severity of adverse effects can be increased when Indapamide is combined with Glycerin.]
[C05AE01, nitroglycerin, The therapeutic efficacy of Indapamide can be increased when used in combination with Nitroglycerin.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Dofetilide.]
[C02CA04, doxazosin, The therapeutic efficacy of Indapamide can be increased when used in combination with Doxazosin.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Indapamide.]
[C07AB09, esmolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Esmolol.]
[M01CB04, aurothioglucose, Indapamide may increase the excretion rate of Aurothioglucose which could result in a lower serum level and potentially a reduction in efficacy.]
[S01LA03, pegaptanib, Indapamide may increase the excretion rate of Pegaptanib which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA09, fosinopril, The therapeutic efficacy of Indapamide can be increased when used in combination with Fosinopril.]
[S01EX01, guanethidine, The therapeutic efficacy of Indapamide can be increased when used in combination with Guanethidine.]
[L02AE03, goserelin, Indapamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Haloperidol.]
[N01AB01, halothane, Halothane may decrease the antihypertensive activities of Indapamide.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Histrelin.]
[N05AH04, quetiapine, Quetiapine may increase the hypotensive activities of Indapamide.]
[N06BX13, idebenone, Indapamide may increase the excretion rate of Idebenone which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Indapamide is combined with Insulin aspart.]
[M04AA01, allopurinol, The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Indapamide.]
[C09CA01, losartan, The therapeutic efficacy of Indapamide can be increased when used in combination with Losartan.]
[B05CB03, magnesium citrate, The risk or severity of adverse effects can be increased when Indapamide is combined with Magnesium citrate.]
[G03DC01, allylestrenol, Indapamide may increase the excretion rate of Allylestrenol which could result in a lower serum level and potentially a reduction in efficacy.]
[A07EC02, mesalamine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Mesalazine.]
[C01CE02, milrinone, Indapamide may increase the excretion rate of Milrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[A12CD02, sodium monofluorophosphate, The risk or severity of adverse effects can be increased when Indapamide is combined with Sodium fluorophosphate.]
[N05CA16, hexobarbital, The risk or severity of hypotension and orthostatic hypotension can be increased when Hexobarbital is combined with Indapamide.]
[R03CC05, hexoprenaline, Hexoprenaline may decrease the antihypertensive activities of Indapamide.]
[C08CA10, nilvadipine, The therapeutic efficacy of Indapamide can be increased when used in combination with Nilvadipine.]
[M02AA26, nimesulide, The therapeutic efficacy of Indapamide can be decreased when used in combination with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Oxatomide.]
[C02DB02, hydralazine, The therapeutic efficacy of Indapamide can be increased when used in combination with Hydralazine.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Indapamide can be increased when used in combination with Hydrochlorothiazide.]
[R05DA03, hydrocodone, The therapeutic efficacy of Indapamide can be decreased when used in combination with Hydrocodone.]
[S02BA01, hydrocortisone, Hydrocortisone may increase the hypokalemic activities of Indapamide.]
[D07AB02, hydrocortisone butyrate, Hydrocortisone butyrate may increase the hypokalemic activities of Indapamide.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Indapamide can be increased when used in combination with Hydroflumethiazide.]
[B05XA17, potassium acetate, Indapamide may increase the excretion rate of Potassium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Indapamide may increase the excretion rate of Hydroxocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD06, propiverine, Indapamide may increase the excretion rate of Propiverine which could result in a lower serum level and potentially a reduction in efficacy.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Hydroxychloroquine.]
[B05AA07, hetastarch, Indapamide may increase the excretion rate of Hydroxyethyl Starch which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Hydroxyzine.]
[C02AC06, rilmenidine, The therapeutic efficacy of Indapamide can be increased when used in combination with Rilmenidine.]
[R02AX02, ibuprofen, The therapeutic efficacy of Indapamide can be decreased when used in combination with Ibuprofen.]
[B05XA08, sodium acetate, Indapamide may increase the excretion rate of Sodium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AD21, sodium tartrate, The risk or severity of adverse effects can be increased when Indapamide is combined with Sodium tartrate.]
[L01AA06, ifosfamide, Indapamide may increase the excretion rate of Ifosfamide which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AH03, sufentanil, The therapeutic efficacy of Indapamide can be decreased when used in combination with Sufentanil.]
[N06AA02, imipramine, Indapamide may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Indapamide is combined with Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Terlipressin.]
[R01AD07, tixocortol, Tixocortol may increase the hypokalemic activities of Indapamide.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Indapamide.]
[L01CE01, topotecan, Indapamide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Pipemidic acid.]
[M01AG01, mefenamic acid, The therapeutic efficacy of Indapamide can be decreased when used in combination with Mefenamic acid.]
[C01DA05, pentaerythritol tetranitrate, Indapamide may increase the excretion rate of Pentaerythritol tetranitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA09, fluticasone furoate, Fluticasone furoate may increase the hypokalemic activities of Indapamide.]
[S01BC01, indomethacin, The therapeutic efficacy of Indapamide can be decreased when used in combination with Indomethacin.]
[C02CA02, indoramin, The therapeutic efficacy of Indapamide can be increased when used in combination with Indoramin.]
[A11HA07, inositol, Indapamide may increase the excretion rate of Inositol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX17, milnacipran, The risk or severity of hyponatremia can be increased when Milnacipran is combined with Indapamide.]
[A03AA30, piperidolate, The serum concentration of Indapamide can be increased when it is combined with Piperidolate.]
[R01AA02, cyclopentamine, The risk or severity of adverse effects can be increased when Indapamide is combined with Cyclopentamine.]
[S01XA28, varenicline, Indapamide may increase the excretion rate of Varenicline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Indapamide.]
[N05BA12, alprazolam, Indapamide may increase the excretion rate of Alprazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH02, ramelteon, Indapamide may increase the excretion rate of Ramelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Indapamide.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Indapamide.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Anagrelide.]
[C07AA01, alprenolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Alprenolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Indapamide may increase the excretion rate of Ipecac which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA13, iprindole, Iprindole may decrease the antihypertensive activities of Indapamide.]
[N06AF05, iproniazid, Iproniazid may increase the hypotensive activities of Indapamide.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypotensive activities of Indapamide.]
[S01EC03, dorzolamide, The therapeutic efficacy of Indapamide can be increased when used in combination with Dorzolamide.]
[R03CC06, isoetharine, Isoetharine may decrease the antihypertensive activities of Indapamide.]
[C09AA16, imidapril, The therapeutic efficacy of Indapamide can be increased when used in combination with Imidapril.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Indapamide.]
[J04AC01, isoniazid, The metabolism of Indapamide can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Indapamide may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CB01, isoproterenol, Isoprenaline may decrease the antihypertensive activities of Indapamide.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Indapamide.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Indapamide is combined with Isosorbide dinitrate.]
[D10BA01, isotretinoin, Indapamide may increase the excretion rate of Isotretinoin which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AA01, isoxsuprine, Isoxsuprine may decrease the antihypertensive activities of Indapamide.]
[S01AA24, kanamycin, Indapamide may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[N01AX03, ketamine, Indapamide may increase the excretion rate of Ketamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02KD01, ketanserin, The therapeutic efficacy of Indapamide can be increased when used in combination with Ketanserin.]
[B01AC22, prasugrel, Indapamide may increase the excretion rate of Prasugrel which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AB02, ketoconazole, The metabolism of Indapamide can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Indapamide.]
[M02AA10, ketoprofen, The risk or severity of adverse effects can be increased when Ketoprofen is combined with Indapamide.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Mizolastine.]
[C01CA22, arbutamine, Arbutamine may decrease the antihypertensive activities of Indapamide.]
[N04BC09, rotigotine, Rotigotine may decrease the antihypertensive activities of Indapamide.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Nalidixic acid.]
[C07AG01, labetalol, The therapeutic efficacy of Indapamide can be increased when used in combination with Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Amantadine.]
[C02AA05, deserpidine, The therapeutic efficacy of Indapamide can be increased when used in combination with Deserpidine.]
[A06AD11, lactulose, The risk or severity of adverse effects can be increased when Indapamide is combined with Lactulose.]
[A06AX03, lubiprostone, The risk or severity of adverse effects can be increased when Indapamide is combined with Lubiprostone.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Indapamide is combined with Levodopa.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Lidoflazine.]
[S01AA21, amikacin, Indapamide may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, Lisuride may decrease the antihypertensive activities of Indapamide.]
[N06AA07, lofepramine, Lofepramine may decrease the antihypertensive activities of Indapamide.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Loperamide.]
[N05BA06, lorazepam, Indapamide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA02, lovastatin, The metabolism of Indapamide can be decreased when combined with Lovastatin.]
[B05XA11, magnesium chloride, Indapamide may increase the excretion rate of Magnesium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BX01, magnesium hydroxide, The risk or severity of adverse effects can be increased when Indapamide is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The risk or severity of adverse effects can be increased when Indapamide is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, The risk or severity of adverse effects can be increased when Indapamide is combined with Magnesium sulfate.]
[L01BA05, pralatrexate, Indapamide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA03, nilotinib, The metabolism of Indapamide can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Indapamide is combined with Mannitol.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Maprotiline.]
[C02BB01, mecamylamine, The therapeutic efficacy of Indapamide can be increased when used in combination with Mecamylamine.]
[R06AE05, meclizine, The serum concentration of Indapamide can be increased when it is combined with Meclizine.]
[M02AA18, meclofenamic acid, The therapeutic efficacy of Indapamide can be decreased when used in combination with Meclofenamic acid.]
[C01AA08, medigoxin, The risk or severity of adverse effects can be increased when Indapamide is combined with Metildigoxin.]
[A06AB07, cascara sagrada, The risk or severity of adverse effects can be increased when Indapamide is combined with Frangula purshiana bark.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Indapamide.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[N06DX01, memantine, Indapamide may increase the excretion rate of Memantine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AB02, meperidine, Indapamide may increase the excretion rate of Meperidine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA11, mephentermine, Mephentermine may decrease the antihypertensive activities of Indapamide.]
[N03AA01, mephobarbital, The risk or severity of hypotension and orthostatic hypotension can be increased when Methylphenobarbital is combined with Indapamide.]
[N01BB03, mepivacaine, Indapamide may increase the excretion rate of Mepivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX05, meptazinol, The therapeutic efficacy of Indapamide can be decreased when used in combination with Meptazinol.]
[G04BX16, tiopronin, Indapamide may increase the excretion rate of Tiopronin which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BC01, mersalyl, Indapamide may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Paliperidone.]
[C01CA09, metaraminol, Metaraminol may decrease the antihypertensive activities of Indapamide.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Indapamide.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Dolasetron.]
[N07BC02, methadone, Indapamide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA03, methamphetamine, Indapamide may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB07, methantheline, The serum concentration of Indapamide can be increased when it is combined with Methantheline.]
[J05AF05, lamivudine, Indapamide may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA30, metharbital, The serum concentration of Indapamide can be increased when it is combined with Metharbital.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, Metergoline may decrease the antihypertensive activities of Indapamide.]
[H03BB02, methimazole, The metabolism of Indapamide can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Indapamide may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[N05CA15, methohexital, The risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Indapamide.]
[A11HA02, pyridoxine, Indapamide may increase the excretion rate of Pyridoxine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Indapamide is combined with Ziconotide.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Indapamide is combined with Methotrexate.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Methotrimeprazine.]
[C01CA10, methoxamine, Methoxamine may decrease the antihypertensive activities of Indapamide.]
[D05BA02, methoxsalen, Indapamide may increase the excretion rate of Methoxsalen which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG09, methoxyflurane, Methoxyflurane may decrease the antihypertensive activities of Indapamide.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Indapamide can be increased when used in combination with Methyclothiazide.]
[A06AC06, methylcellulose, The risk or severity of adverse effects can be increased when Indapamide is combined with Methylcellulose.]
[C02AB01, methyldopa, The therapeutic efficacy of Indapamide can be increased when used in combination with Methyldopa.]
[V04CG05, methylene blue, Methylene blue may increase the hypotensive activities of Indapamide.]
[G02AB01, methylergonovine, Methylergometrine may decrease the antihypertensive activities of Indapamide.]
[N06BA04, methylphenidate, Methylphenidate may decrease the antihypertensive activities of Indapamide.]
[H02AB04, methylprednisolone, Methylprednisolone may increase the hypokalemic activities of Indapamide.]
[D07AC14, methylprednisolone aceponate, Methylprednisolone aceponate may increase the hypokalemic activities of Indapamide.]
[G03EK01, methyltestosterone, Indapamide may increase the excretion rate of Methyltestosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA04, methysergide, Methysergide may decrease the antihypertensive activities of Indapamide.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Metoclopramide.]
[C03BA08, metolazone, The therapeutic efficacy of Indapamide can be increased when used in combination with Metolazone.]
[C07AB02, metoprolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Metronidazole.]
[V04CD01, metyrapone, Indapamide may increase the excretion rate of Metyrapone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX03, mianserin, Mianserin may decrease the antihypertensive activities of Indapamide.]
[S02AA13, miconazole, The metabolism of Indapamide can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Aminophenazone.]
[N05CD08, midazolam, Indapamide may increase the excretion rate of Midazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA17, midodrine, Midodrine may decrease the antihypertensive activities of Indapamide.]
[G03XB01, mifepristone, The therapeutic efficacy of Mifepristone can be decreased when used in combination with Indapamide.]
[A06AA01, mineral oil, The risk or severity of adverse effects can be increased when Indapamide is combined with Mineral oil.]
[J05AH01, zanamivir, Indapamide may increase the excretion rate of Zanamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[D11AX01, minoxidil, The therapeutic efficacy of Indapamide can be increased when used in combination with Minoxidil.]
[L01XX23, mitotane, The metabolism of Indapamide can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may decrease the antihypertensive activities of Indapamide.]
[L03AC01, aldesleukin, Indapamide may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01DX12, molsidomine, Molsidomine may increase the hypotensive activities of Indapamide.]
[C01BD01, amiodarone, The metabolism of Indapamide can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Indapamide may increase the excretion rate of Amitriptyline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AA01, morphine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Morphine.]
[A04AA05, palonosetron, Indapamide may increase the excretion rate of Palonosetron which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Indapamide may increase the excretion rate of Certolizumab pegol which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BA01, ammonium chloride, Indapamide may increase the excretion rate of Ammonium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Pazopanib.]
[L04AA06, mycophenolic acid, Indapamide may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC03, vecuronium, The serum concentration of Indapamide can be increased when it is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of hypotension and orthostatic hypotension can be increased when Amobarbital is combined with Indapamide.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Indapamide.]
[G04CA04, silodosin, The risk or severity of orthostatic hypotension and dizziness can be increased when Indapamide is combined with Silodosin.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Indapamide.]
[N03AB05, fosphenytoin, The metabolism of Indapamide can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Nadolol.]
[J01CA04, amoxicillin, Indapamide may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Indapamide.]
[N02AF02, nalbuphine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Indapamide can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The therapeutic efficacy of Indapamide can be decreased when used in combination with Naltrexone.]
[S01GA01, naphazoline, Naphazoline may decrease the antihypertensive activities of Indapamide.]
[N06BA01, amphetamine, Indapamide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA12, naproxen, The therapeutic efficacy of Indapamide can be decreased when used in combination with Naproxen.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Indapamide.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Indapamide is combined with Duloxetine.]
[N04BX01, tolcapone, Indapamide may increase the excretion rate of Tolcapone which could result in a lower serum level and potentially a reduction in efficacy.]
[S03AA01, neomycin, Indapamide may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The therapeutic efficacy of Indapamide can be decreased when used in combination with Remifentanil.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Indapamide.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Levosimendan.]
[B01AC17, tirofiban, Indapamide may increase the excretion rate of Tirofiban which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Indapamide.]
[S01AA19, ampicillin, Indapamide may increase the excretion rate of Ampicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AX16, plerixafor, Indapamide may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA23, netilmicin, Indapamide may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of hyponatremia can be increased when Desvenlafaxine is combined with Indapamide.]
[C09CA07, telmisartan, The therapeutic efficacy of Indapamide can be increased when used in combination with Telmisartan.]
[J05AB11, valacyclovir, Indapamide may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[H05BX02, paricalcitol, The risk or severity of hypokalemia can be increased when Paricalcitol is combined with Indapamide.]
[C01CE01, inamrinone, Indapamide may increase the excretion rate of Amrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF02, nialamide, Nialamide may increase the hypotensive activities of Indapamide.]
[C08CA04, nicardipine, The therapeutic efficacy of Indapamide can be increased when used in combination with Nicardipine.]
[C04AE02, nicergoline, Nicergoline may decrease the antihypertensive activities of Indapamide.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Indapamide is combined with Nicotine.]
[C08CA05, nifedipine, Indapamide may increase the excretion rate of Nifedipine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA17, niflumic acid, The therapeutic efficacy of Indapamide can be decreased when used in combination with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Indapamide is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The therapeutic efficacy of Indapamide can be increased when used in combination with Nimodipine.]
[C08CA07, nisoldipine, The therapeutic efficacy of Indapamide can be increased when used in combination with Nisoldipine.]
[C08CA08, nitrendipine, The therapeutic efficacy of Indapamide can be increased when used in combination with Nitrendipine.]
[R07AX01, nitric oxide, Indapamide may increase the excretion rate of Nitric Oxide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XE01, nitrofurantoin, Indapamide may increase the excretion rate of Nitrofurantoin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF03, zaleplon, Indapamide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC05, pramipexole, Indapamide may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DD01, nitroprusside, The therapeutic efficacy of Indapamide can be increased when used in combination with Nitroprusside.]
[N01AX13, nitrous oxide, Nitrous oxide may decrease the antihypertensive activities of Indapamide.]
[C01CA03, norepinephrine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Indapamide.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Norfloxacin.]
[C02KX01, bosentan, The therapeutic efficacy of Indapamide can be increased when used in combination with Bosentan.]
[N06AA10, nortriptyline, The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Indapamide.]
[G02CA02, nylidrin, Nylidrin may decrease the antihypertensive activities of Indapamide.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Indapamide.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Ofloxacin.]
[N06AA05, opipramol, Opipramol may decrease the antihypertensive activities of Indapamide.]
[N02AA02, opium, Indapamide may increase the excretion rate of Opium which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CB03, metaproterenol, Orciprenaline may decrease the antihypertensive activities of Indapamide.]
[G04CA02, tamsulosin, Indapamide may increase the excretion rate of Tamsulosin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01AC01, ouabain, The risk or severity of adverse effects can be increased when Indapamide is combined with Ouabain.]
[J01CF04, oxacillin, Indapamide may increase the excretion rate of Oxacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA04, oxazepam, Indapamide may increase the excretion rate of Oxazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Oxolinic acid.]
[C07AA02, oxprenolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Oxprenolol.]
[N02AA05, oxycodone, The therapeutic efficacy of Indapamide can be decreased when used in combination with Oxycodone.]
[C01DX03, oxyfedrine, Oxyfedrine may decrease the antihypertensive activities of Indapamide.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Indapamide can be decreased when used in combination with Oxymetazoline.]
[N02AA11, oxymorphone, The therapeutic efficacy of Indapamide can be decreased when used in combination with Oxymorphone.]
[S01BC02, oxyphenbutazone, The therapeutic efficacy of Indapamide can be decreased when used in combination with Oxyphenbutazone.]
[A03AB03, oxyphenonium, The serum concentration of Indapamide can be increased when it is combined with Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Indapamide.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Asenapine.]
[N02AX06, tapentadol, The therapeutic efficacy of Indapamide can be decreased when used in combination with Tapentadol.]
[M03AC01, pancuronium, The serum concentration of Indapamide can be increased when it is combined with Pancuronium.]
[J04AB30, capreomycin, Indapamide may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Papaverine.]
[H02AB05, paramethasone, Paramethasone may increase the hypokalemic activities of Indapamide.]
[C02KC01, pargyline, The therapeutic efficacy of Indapamide can be increased when used in combination with Pargyline.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Indapamide.]
[G04BD11, fesoterodine, Indapamide may increase the excretion rate of Fesoterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA23, penbutolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Penfluridol.]
[J01CE09, penicillin G procaine, Indapamide may increase the excretion rate of Procaine benzylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA14, penicillin G, Indapamide may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, The metabolism of Indapamide can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Indapamide may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Pentoxifylline may increase the hypotensive activities of Indapamide.]
[N04BC02, pergolide, Pergolide may decrease the antihypertensive activities of Indapamide.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Perhexiline.]
[N02AD02, phenazocine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Phenazocine.]
[G04BX06, phenazopyridine, Indapamide may increase the excretion rate of Phenazopyridine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF03, phenelzine, Phenelzine may increase the hypotensive activities of Indapamide.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Indapamide.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Pheniramine.]
[N03AA02, phenobarbital, The metabolism of Indapamide can be increased when combined with Phenobarbital.]
[A06AB01, oxyphenisatin, The risk or severity of adverse effects can be increased when Indapamide is combined with Oxyphenisatin.]
[N01AH04, phenoperidine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Phenoperidine.]
[C04AX02, phenoxybenzamine, The therapeutic efficacy of Indapamide can be increased when used in combination with Phenoxybenzamine.]
[A08AA01, phentermine, Phentermine may decrease the antihypertensive activities of Indapamide.]
[V03AB36, phentolamine, The therapeutic efficacy of Indapamide can be increased when used in combination with Phentolamine.]
[M02AA01, phenylbutazone, The therapeutic efficacy of Indapamide can be decreased when used in combination with Phenylbutazone.]
[S01GA05, phenylephrine, Phenylephrine may decrease the antihypertensive activities of Indapamide.]
[R01BA01, phenylpropanolamine, Phenylpropanolamine may decrease the antihypertensive activities of Indapamide.]
[N03AB02, phenytoin, The metabolism of Indapamide can be increased when combined with Phenytoin.]
[S01AE05, levofloxacin, Indapamide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[B02BA01, vitamin K1, Indapamide may increase the excretion rate of Phylloquinone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AB12, cidofovir, Indapamide may increase the excretion rate of Cidofovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CX01, mibefradil, The therapeutic efficacy of Indapamide can be increased when used in combination with Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Pimozide.]
[C07AA03, pindolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Pindolol.]
[J01CA12, piperacillin, Indapamide may increase the excretion rate of Piperacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE01, saquinavir, The metabolism of Indapamide can be decreased when combined with Saquinavir.]
[N06BX03, piracetam, Indapamide may increase the excretion rate of Piracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA02, eprosartan, The therapeutic efficacy of Indapamide can be increased when used in combination with Eprosartan.]
[A02BX03, pirenzepine, The serum concentration of Indapamide can be increased when it is combined with Pirenzepine.]
[N02AC03, pirinitramide, The therapeutic efficacy of Indapamide can be decreased when used in combination with Piritramide.]
[S01BC06, piroxicam, The therapeutic efficacy of Indapamide can be decreased when used in combination with Piroxicam.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Grepafloxacin.]
[N02CX01, pizotyline, Pizotifen may decrease the antihypertensive activities of Indapamide.]
[J05AG02, delavirdine, The metabolism of Indapamide can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The therapeutic efficacy of Indapamide can be increased when used in combination with Irbesartan.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Indapamide.]
[A06AD15, polyethylene glycols, The risk or severity of adverse effects can be increased when Indapamide is combined with Polyethylene glycol.]
[C03AA05, polythiazide, The therapeutic efficacy of Indapamide can be increased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Indapamide can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Indapamide.]
[B05XA01, potassium chloride, Indapamide may increase the excretion rate of Potassium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Indapamide is combined with Insulin lispro.]
[C07AB01, practolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Prajmaline.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Indapamide.]
[S03BA02, prednisolone, Prednisolone may increase the hypokalemic activities of Indapamide.]
[H02AB07, prednisone, Prednisone may increase the hypokalemic activities of Indapamide.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Prenylamine.]
[P01BA03, primaquine, The metabolism of Indapamide can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Indapamide can be increased when combined with Primidone.]
[M04AB01, probenecid, Indapamide may increase the excretion rate of Probenecid which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Probucol.]
[C01BA02, procainamide, Indapamide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, Procaine may increase the hypotensive activities of Indapamide.]
[L01XB01, procarbazine, Procarbazine may increase the hypotensive activities of Indapamide.]
[C10AB05, fenofibrate, Indapamide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Prochlorperazine.]
[N04AA04, procyclidine, The serum concentration of Indapamide can be increased when it is combined with Procyclidine.]
[N05AA03, promazine, Promazine may decrease the antihypertensive activities of Indapamide.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Promethazine.]
[C01BC03, propafenone, Propafenone may decrease the antihypertensive activities of Indapamide.]
[A03AB05, propantheline, Indapamide may increase the excretion rate of Propantheline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC01, periciazine, Periciazine may decrease the antihypertensive activities of Indapamide.]
[N05CM06, propiomazine, Propiomazine may decrease the antihypertensive activities of Indapamide.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Propofol.]
[N02AC04, propoxyphene, The therapeutic efficacy of Indapamide can be decreased when used in combination with Dextropropoxyphene.]
[C07AA05, propranolol, The therapeutic efficacy of Indapamide can be increased when used in combination with Propranolol.]
[C01AB01, proscillaridin, The risk or severity of adverse effects can be increased when Indapamide is combined with Proscillaridin.]
[N02CC04, rizatriptan, Indapamide may increase the excretion rate of Rizatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC09, epoprostenol, The therapeutic efficacy of Indapamide can be increased when used in combination with Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Indapamide.]
[R01BA02, pseudoephedrine, Pseudoephedrine may decrease the antihypertensive activities of Indapamide.]
[N05AX12, aripiprazole, The risk or severity of hypotension can be increased when Aripiprazole is combined with Indapamide.]
[N07XX07, dalfampridine, Indapamide may increase the excretion rate of Dalfampridine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB15, diphemanil, The serum concentration of Indapamide can be increased when it is combined with Diphemanil.]
[A03AB09, isopropamide, The serum concentration of Indapamide can be increased when it is combined with Isopropamide.]
[S01FA03, methscopolamine, The serum concentration of Indapamide can be increased when it is combined with Methscopolamine.]
[N05CA07, talbutal, The serum concentration of Indapamide can be increased when it is combined with Talbutal.]
[P02CC01, pyrantel, Indapamide may increase the excretion rate of Pyrantel which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK01, pyrazinamide, Indapamide may increase the excretion rate of Pyrazinamide which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Mepyramine.]
[C01BA01, quinidine, Indapamide may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[P01BC01, quinine, The therapeutic efficacy of Quinine can be decreased when used in combination with Indapamide.]
[A02BA02, ranitidine, Indapamide may increase the excretion rate of Ranitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA01, rescinnamine, The therapeutic efficacy of Indapamide can be increased when used in combination with Rescinnamine.]
[C02AA02, reserpine, The therapeutic efficacy of Indapamide can be increased when used in combination with Reserpine.]
[J05AP01, ribavirin, Indapamide may increase the excretion rate of Ribavirin which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AB02, rifampin, The metabolism of Indapamide can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, Rimiterol may decrease the antihypertensive activities of Indapamide.]
[G02CA01, ritodrine, Ritodrine may decrease the antihypertensive activities of Indapamide.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Roxithromycin.]
[N02BA05, salicylamide, The therapeutic efficacy of Indapamide can be decreased when used in combination with Salicylamide.]
[A07EC01, sulfasalazine, The therapeutic efficacy of Indapamide can be decreased when used in combination with Sulfasalazine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Indapamide can be decreased when used in combination with Salicylic acid.]
[S01FA02, scopolamine, The serum concentration of Indapamide can be increased when it is combined with Scopolamine.]
[N05CA06, secobarbital, The risk or severity of hypotension and orthostatic hypotension can be increased when Secobarbital is combined with Indapamide.]
[N04BD01, selegiline, Selegiline may increase the hypotensive activities of Indapamide.]
[L01FA03, obinutuzumab, Indapamide may increase the hypotensive activities of Obinutuzumab.]
[J01GB08, sisomicin, Indapamide may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Indapamide may increase the excretion rate of Sodium fluoride which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CC01, sorbitol, The risk or severity of adverse effects can be increased when Indapamide is combined with Sorbitol.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Sotalol.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01DA14, isosorbide mononitrate, Indapamide may increase the excretion rate of Isosorbide mononitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[H02CA04, levoketoconazole, The metabolism of Indapamide can be decreased when combined with Levoketoconazole.]
[D10AX03, azelaic acid, Indapamide may increase the excretion rate of Azelaic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AE11, tiaprofenic acid, The therapeutic efficacy of Indapamide can be decreased when used in combination with Tiaprofenic acid.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A12AA11, calcium pangamate, Indapamide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level.]
[R03BB01, ipratropium bromide, The serum concentration of Indapamide can be increased when it is combined with Ipratropium.]
